Please login to the form below
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.
Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.
This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.
Topics covered in the webcast include:
- The European RA market
- Current status and market situation of JAK inhibitors (key EU5 countries)
- Uptake curve of JAKS compared to other new entrants and biosimilars
- The patient profile and unmet needs in RA
- Profile of physicians prescribing JAKS
- Country differences
- The future of new classes of JAK inhibitors
Company Details
Research Partnership
Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom
Latest content on this profile
- Article: Creating truly effective communications - the impact of high speed, high octane messaging
- In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.
Research Partnership
- Research Partnership makes two senior appointments to bolster its US and MedTech operations
- Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.
Research Partnership
- Case study: How segmentation of treaters guided a novel product launch in the allergy space
- Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment of Serious Allergic Reactions.
Research Partnership
- Article: War in the Blood - The battle takes shape in the burgeoning European oncology CAR-T market access space
- Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum's Deep Dive.
Research Partnership
- Research Partnership wins prestigious 2023 BOBI Award
- We are delighted to announce Research Partnership were announced the winners in the ‘Creative Fieldwork Team of the Year’ category at the BHBIA’s Best of Business Intelligence (BOBI) Awards.
Research Partnership
- Case study: How we provided in-depth knowledge of electrosurgical generators among target segments and settings in the US market
- Find out how we helped our client to identify clinician roles and responsibilities, pain points and drivers and barriers with respect to a current medical device.
Research Partnership
